Trial Profile
An Observational Post-Marketing Safety Registry Of Patients Who Have Been Prescribed Sativex
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Dec 2022
Price :
$35
*
At a glance
- Drugs Nabiximols (Primary)
- Indications Cancer pain; Diabetic neuropathies; Multiple sclerosis; Muscle spasticity; Neuropathic pain
- Focus Adverse reactions
- Sponsors Jazz Pharmaceuticals Inc
- 28 Oct 2022 Results of post hoc analysis assessing the long-term dosage of nabiximols, to evaluate real-world dosing and to investigate the association between dosage and premature study discontinuation in MS-related spasticity from GWMS1137 (n=62) and GWSR10128 (N=765) studies, presented at the 38th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
- 10 Oct 2017 Status changed from recruiting to completed.
- 10 Oct 2015 Final results of patients from the United Kingdom (n=941) presented at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis.